- Home
- MRKR vs BRTX Comparison
MRKR vs BRTX Comparison
Compare MRKR & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRKR
- BRTX
- Stock Information
- Founded
- MRKR N/A
- BRTX 1997
- Country
- MRKR United States
- BRTX United States
- Employees
- MRKR N/A
- BRTX N/A
- Industry
- MRKR Biotechnology: Pharmaceutical Preparations
- BRTX Managed Health Care
- Sector
- MRKR Health Care
- BRTX Health Care
- Exchange
- MRKR Nasdaq
- BRTX Nasdaq
- Market Cap
- MRKR 11.6M
- BRTX 12.8M
- IPO Year
- MRKR N/A
- BRTX N/A
- Fundamental
- Price
- MRKR $0.94
- BRTX $1.41
- Analyst Decision
- MRKR Strong Buy
- BRTX
- Analyst Count
- MRKR 2
- BRTX 0
- Target Price
- MRKR $10.25
- BRTX N/A
- AVG Volume (30 Days)
- MRKR 156.4K
- BRTX 294.1K
- Earning Date
- MRKR 11-14-2025
- BRTX 11-12-2025
- Dividend Yield
- MRKR N/A
- BRTX N/A
- EPS Growth
- MRKR N/A
- BRTX N/A
- EPS
- MRKR N/A
- BRTX N/A
- Revenue
- MRKR $5,388,071.00
- BRTX $605,200.00
- Revenue This Year
- MRKR N/A
- BRTX $232.67
- Revenue Next Year
- MRKR $9.06
- BRTX $52.92
- P/E Ratio
- MRKR N/A
- BRTX N/A
- Revenue Growth
- MRKR 44.55
- BRTX 247.62
- 52 Week Low
- MRKR $0.81
- BRTX $1.19
- 52 Week High
- MRKR $5.95
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- MRKR 46.45
- BRTX 37.90
- Support Level
- MRKR $0.84
- BRTX $1.32
- Resistance Level
- MRKR $1.02
- BRTX $1.45
- Average True Range (ATR)
- MRKR 0.05
- BRTX 0.10
- MACD
- MRKR -0.00
- BRTX -0.02
- Stochastic Oscillator
- MRKR 46.38
- BRTX 17.95
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.